- Trial phase
- Approved
- Time to market
- Already approved and marketed in the US since 2004 (Octagam 5%) and 2014/2015/2021 (Octagam 10% for various indications).
- Why 3/10
- No hard, dated binary catalyst is scheduled for Octagam in the next ~12 months; the drug is already approved and marketed across all its indications. The impact score is low (3) because Octagam is a mature, commercialized product with no pending regulatory decision and represents a negligible fraction of Pfizer's $62-64B annual revenue.
Octagam is an already-approved, marketed IVIg product with no pending FDA decision or pivotal readout. For Pfizer investors, this drug is immaterial to the stock thesis; watch the broader IVIg market for pricing and supply dynamics, but Octagam alone will not move PFE shares.
Price Chart
Executive Summary
Octagam (immune globulin intravenous, human) is an IVIg product developed by privately held Octapharma AG and marketed in the US by Pfizer under a license agreement. FDA-approved since 2004 for primary humoral immunodeficiency, with later approvals for chronic ITP (2015) and adult dermatomyositis (2021, with orphan exclusivity through 2028). The drug is a mature, commercialized product with no pending regulatory catalysts. For Pfizer, a $62-64B revenue company, Octagam is a minor product in a crowded IVIg market and is not a material stock driver.
How It Works
Octagam is an intravenous immunoglobulin (IVIg) product made from purified human antibodies (immunoglobulin G) collected from thousands of healthy plasma donors. When infused into a patient, it provides a broad supply of ready-made antibodies that bolster the immune system to fight infections (in immunodeficiency), block harmful immune cells from destroying platelets (in ITP), and reduce inflammation in muscles and skin (in dermatomyositis).
Trial Status
Octagam is fully FDA-approved and commercially available in the US. Octagam 5% was initially approved May 21, 2004 for primary humoral immunodeficiency. Octagam 10% was approved September 2015 for chronic ITP and July 2021 for adult dermatomyositis (with 7-year orphan drug exclusivity). An additional FDA approval letter was issued April 1, 2022 for both concentrations.
The Two-Sided Case
Upcoming Catalysts
- No upcoming binary catalysts identified; Octagam is a mature, approved product with no pending PDUFA dates, label-expansion filings, or pivotal readouts.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
PFIZER INC 8-K PFE ·Originating report